Abstract
Gold nanoparticles are becoming a promising platform for the delivery of drugs to treat neurodegenerative diseases. Parkinson's disease, associated with the aggregation of α-synuclein, is a condition that results in dysfunctional neuronal cells leading to their degeneration and death. Oxidative stress has been strongly implicated as a common feature in this process. The limited efficacy of the traditional therapies and the development of associated severe side effects present an unmet need for preventive and adjuvant therapies. The organosulfur compound lipoic acid, naturally located in the mitochondria, plays a powerful antioxidative role against oxidative stress. However, the efficacy is limited by its low physiological concentration, and the administration is affected by its short half-life and bioavailability due to hepatic degradation. Here we exploited the drug delivery potential of gold nanoparticles to assemble lipoic acid, and administered the system into SH-SY5Y cells, a cellular model commonly used to study Parkinson's disease. We tested the nanoconjugates of GNPs–LA, under an oxidative environment induced by gold nanoparticle/α-synuclein conjugates (GNPs–α-Syn). GNPs–LA were found to be biocompatible and capable of restoring the cell damage caused by high-level reactive oxygen species generated by excessive oxidative stress in the cellular environment. We conclude that GNPs–LA may serve as promising drug delivery vehicles conveying antioxidant molecules for the treatment of Parkinson's disease.
Highlights
Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide
The present study began with the synthesis and characterization of bare gold nanoparticles (GNPs)[38,39] which were conjugated with lipoic acid (GNPs–LA)[40,41] and a-synuclein (GNPs–aSyn).[34,42]
The absorption peak at 480 nm of GNPs was attributed to the surface plasmon absorption of 20 nm spherical gold nanoparticles whereas, a er the conjugation, a slight broadening of peaks was observed for both GNPs–LA and GNPs–a-Syn, in accordance with Dynamic light scattering (DLS) results (Fig. 2b)
Summary
Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. When the cells were exposed to the nanoparticles for a prolonged time (12 h and 72 h), an increase in the cellular internalization of GNPs–LA was observed in comparison to GNPs–a-Syn at the same injected doses
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
